SIP
INSM icon

Stoneridge Investment Partners’s Insmed INSM Stock Holding History

Stoneridge Investment Partners’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-30,275
Closed -$520K – 268
2017
Q2 		$520K Buy
+30,275
New +$517K 0.08% 148

Other funds holding INSM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Stoneridge Investment Partners's INSM Position: Q3 2017 in Review

Stoneridge Investment Partners sold out of Insmed (INSM) in Q3 2017, closing a stake of 30,275 shares — an estimated $520K sold.

Stoneridge Investment Partners first reported a position in INSM in Q2 2017 and held it in 1 quarter. The position peaked at $520K in Q2 2017. 146 funds tracked by Wall St. Rank hold INSM as of Q3 2017.

  • Stoneridge Investment Partners reported no remaining Insmed position as of Q3 2017 after selling out during the quarter.
  • Stoneridge Investment Partners sold 30,275 Insmed shares in Q3 2017, an estimated $520K.
  • Stoneridge Investment Partners first reported a position in Insmed in Q2 2017 and held it in 1 quarter.
  • Stoneridge Investment Partners's Insmed position peaked at $520K in Q2 2017.
  • 146 funds tracked by Wall St. Rank held Insmed as of Q3 2017.

Based on Stoneridge Investment Partners's 13F filing for Q3 2017, filed 2 Nov 2017.